CG Oncology, Inc. (CGON) · Aug 6, 2026 · Company update

EPS missed expectations, while a new $500 million ATM adds dilution overhang

EPS missed expectations, while a new $500 million ATM adds dilution overhang

The quarter’s EPS was worse than expected. CG Oncology reported a net loss of $0.90 per share versus published pre-release estimates of roughly $0.66–$0.68 per share loss, a clear miss; revenue comparisons are less reliable because available estimates were inconsistent. (Income Statement)

$ millions, except per-share dataQ2 2026Q2 2025Change / comparison
Total revenue$1.157$0.000New commercial and development revenue (Income Statement)
R&D expense$54.657$31.331Higher (Income Statement)
G&A expense$28.976$17.410Higher (Income Statement)
Net loss$(79.056)$(41.426)Larger loss (Income Statement)
Net loss per share$(0.90)$(0.54)Worse by $0.36 (Income Statement)
Cash, cash equivalents and marketable securities$1,028.278$742.155 at Dec. 31, 2025Company says runway through 2029 (Balance Sheet Data; Financial Highlights)

The more consequential update is the financing capacity. The company registered an additional $500.0 million of common-stock sales under its ATM facility after previously selling approximately $550.0 million through the same agreement (Item 8.01). This does not mean all $500 million will be issued immediately, but it materially expands potential dilution and signals that management wants financing flexibility ahead of pivotal clinical and regulatory milestones.

The pipeline timetable was maintained, not accelerated. PIVOT-006 topline data remain anticipated in the near term, and BLA completion for the high-risk BCG-unresponsive indication remains targeted for the fourth quarter of 2026 (Anticipated 2026 Milestones). The filing provides no new efficacy data, so the central investment question remains unresolved until the Phase 3 readout.

Cash strength offsets some financing concern but does not erase the miss. Cash fell from approximately $1.1 billion at March 31, 2026 to approximately $1.0 billion at June 30, 2026, while R&D increased to $54.7 million from $31.3 million year over year and G&A rose to $29.0 million from $17.4 million (Financial Highlights). The company still claims funding through 2029, but the weaker-than-expected quarterly loss plus expanded ATM creates a mildly negative read ahead of the more important clinical catalysts.

Original filing on SEC EDGAR

More CG Oncology, Inc. news

EPS missed expectations, while a new $500 million ATM adds dilution overhang | CGON Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.